Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
McDonald's
MCD
|
+$770M |
| 2 |
Crown Castle
CCI
|
+$678M |
| 3 |
ATVI
Activision Blizzard
ATVI
|
+$557M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$437M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$305M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nike
NKE
|
+$1.22B |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$1.04B |
| 3 |
Amazon
AMZN
|
+$661M |
| 4 |
SHPG
Shire pic
SHPG
|
+$478M |
| 5 |
TWX
Time Warner Inc
TWX
|
+$457M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.25% |
| 2 | Consumer Discretionary | 17.77% |
| 3 | Healthcare | 14.23% |
| 4 | Communication Services | 13.04% |
| 5 | Financials | 10.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
626
Cardinal Health
CAH
$54.6B
| $327K | ﹤0.01% |
+4,200
| New | +$317K |
|
|
FNSR
627
DELISTED
Finisar Corp
FNSR
| $322K | ﹤0.01% |
12,409
+4,839
| +64% | +$121K |
|
628
Eldorado Gold
EGO
$11.9B
| $312K | ﹤0.01% |
23,517
-862,889
| -97% | -$14.1M |
|
629
Repligen
RGEN
$9.95B
| $291K | ﹤0.01% |
+7,026
| New | +$267K |
|
|
BSFT
630
DELISTED
BroadSoft, Inc.
BSFT
| $273K | ﹤0.01% |
6,340
-13,526
| -68% | -$531K |
|
631
Coherus Oncology
CHRS
$218M
| $261K | ﹤0.01% |
18,200
+69
| +0.4% | +$1.33K |
|
|
BIG
632
DELISTED
Big Lots, Inc.
BIG
| $259K | ﹤0.01% |
5,352
+347
| +7% | +$16.9K |
|
633
Invesco
IVZ
$14.5B
| $215K | ﹤0.01% |
6,100
-25,565
| -81% | -$833K |
|
634
Agilent Technologies
A
$43.4B
| $212K | ﹤0.01% |
+3,569
| New | +$203K |
|
635
Progressive
PGR
$127B
| $206K | ﹤0.01% |
4,665
-24,492
| -84% | -$1.02M |
|
636
iShares Biotechnology ETF
IBB
$10.5B
| $202K | ﹤0.01% |
+1,950
| New | +$192K |
|
637
Accenture
ACN
$116B
| $201K | ﹤0.01% |
+1,622
| New | +$198K |
|
638
Arbutus Biopharma
ABUS
$1B
| – | – |
-140,019
| Closed | -$455K |
|
639
Amgen
AMGN
$234B
| – | – |
-1,702
| Closed | -$279K |
|
640
Atara Biotherapeutics
ATRA
$92.3M
| – | – |
-1,614
| Closed | -$829K |
|
|
VISN
641
Vistance Networks Inc
VISN
$1.4B
| – | – |
-889,636
| Closed | -$37.1M |
|
642
Dover
DOV
$26.8B
| – | – |
-441,293
| Closed | -$28.6M |
|
643
Darden Restaurants
DRI
$24.5B
| – | – |
-9,927
| Closed | -$831K |
|
644
Ecolab
ECL
$80.4B
| – | – |
-2,675
| Closed | -$335K |
|
645
IMAX
IMAX
$2.76B
| – | – |
-7,978
| Closed | -$271K |
|
646
CALL
Incyte
INCY
$25.2B
| – | – |
-70,000
| Closed | -$9.36M |
|
647
Independent Bank
INDB
$3.89B
| – | – |
-4,060
| Closed | -$264K |
|
|
IPG
648
DELISTED
Interpublic Group of Companies
IPG
| – | – |
-32,418
| Closed | -$797K |
|
649
PUT
iShares Russell 2000 ETF
IWM
$80.8B
| – | – |
-1,000,000
| Closed | -$137M |
|
650
Lazard
LAZ
$4.25B
| – | – |
-8,385
| Closed | -$386K |
|
Similar funds
Jennison Associates's Q2 2017 Portfolio in Review
As of Q2 2017, Jennison Associates held 698 positions worth $94.3B, up 1.1% from $93.2B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Jennison Associates withdrew a net $3.11B in Q2 2017, closing 61 positions and reducing 332 holdings. Its most notable exit was NXP Semiconductors, an estimated $452M position sold in full.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 21% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Jennison Associates opened a new position in Newell Brands worth $125M.
- Jennison Associates's largest Q2 2017 buy was Newell Brands: 2,328,211 shares worth $125M.
- Jennison Associates added most to McDonald's in Q2 2017, an estimated $770M increase.
- Jennison Associates's biggest Q2 2017 reduction was Nike, cutting an estimated $1.22B.
- Jennison Associates fully exited NXP Semiconductors in Q2 2017, selling an estimated $452M.
- Jennison Associates's ten largest holdings make up 27% of its $94.3B portfolio in Q2 2017.
- Jennison Associates opened 62 new positions and closed 61 in Q2 2017.
- Jennison Associates's portfolio value rose 1.1% quarter-over-quarter to $94.3B.
Based on Jennison Associates's 13F filing for Q2 2017, filed 4 Aug 2017.